What Is PSA Testing?
The PSA (Prostate-Specific Antigen) test is a simple blood draw that measures a protein produced by the prostate gland. Elevated levels can signal prostate cancer — but they can also result from an enlarged prostate, a recent infection, or even a long bike ride. That ambiguity is both the test's power and its biggest problem.
Available at every major lab and most primary care offices, PSA testing costs between $30 and $80 without insurance — making it one of the cheapest cancer screening tools available. The test takes under 5 minutes: a standard blood draw, results in 1–3 days. No prep, no fasting, no discomfort beyond the needle.
Developed in the 1980s and adopted widely in the 1990s, PSA screening is credited with contributing to the ~50% decline in prostate cancer mortality since its peak. But the screening landscape has become more nuanced — major medical organizations now recommend shared decision-making rather than universal testing. This review breaks down exactly what the data says.
How PSA Testing Works
PSA is produced by both normal and cancerous prostate cells. The test measures PSA concentration in nanograms per milliliter (ng/mL) of blood. A result of 4.0 ng/mL has traditionally been the threshold for "elevated" — but that line is blurrier than most men realize.
What Can Skew Your Results
PSA isn't a static number. Ejaculation within 48 hours, vigorous exercise, prostate infection (prostatitis), and benign prostatic hyperplasia (BPH) can all elevate levels. A digital rectal exam before the blood draw can also cause a temporary spike. For the most accurate reading, avoid ejaculation and intense exercise for 48 hours beforehand, and tell your doctor about any recent UTI symptoms.
What Your Doctor Orders
Most standard panels include total PSA. Your doctor may also order free PSA (the percentage of PSA circulating unbound to proteins — lower percentages correlate with higher cancer risk) or PSA velocity (the rate of change over time — a rise faster than 0.75 ng/mL per year warrants attention regardless of the absolute number).
The Real Data: What PSA Testing Actually Catches
We reviewed clinical trial data, USPSTF analysis, and screening program outcomes to present the numbers that matter. Here's what PSA testing actually delivers — and where it falls short.
The PLCO and ERSPC Trials
The two largest randomized trials tell different stories. The European ERSPC trial found PSA screening reduced prostate cancer mortality by 21% over 13 years. The American PLCO trial found no benefit — but its control group was heavily contaminated (many "control" men got PSA tests independently). When reanalyzed accounting for contamination, the PLCO data aligns closer to the European findings.
Overdiagnosis Is the Real Cost
An estimated 20–50% of screen-detected prostate cancers are overdiagnosed — meaning they would never have caused symptoms or death during the patient's lifetime. These slow-growing tumors are often managed with active surveillance, but the initial detection triggers a cascade: biopsies (infection risk, bleeding), anxiety, and sometimes unnecessary treatment with real side effects including incontinence and erectile dysfunction.
Pros & Cons
Pros
- One of few available prostate cancer screening tools
- Simple blood draw — no prep, no fasting, under 5 minutes
- Costs $30–80 out of pocket, covered by most insurance
- Contributes to catching cancers at curable stages (I–II)
- Enables tracking PSA velocity over time for risk trends
- Available at virtually every lab and primary care office
Cons
- 75% false positive rate at the 4.0 ng/mL threshold
- Leads to unnecessary biopsies (infection risk, anxiety)
- ~15% of aggressive cancers produce PSA below 4.0
- Cannot distinguish aggressive from slow-growing cancer
- Overdiagnosis leads to treatment side effects in some men
- Many factors skew results (exercise, sex, infection, age)
Who Should Get PSA Testing
Ideal Candidates
- Men 50–69 years old — The USPSTF gives a Grade C recommendation ("individual decision") for this age group, meaning the net benefit is moderate and the decision should be shared with a doctor.
- Men with family history — If a father, brother, or uncle was diagnosed with prostate cancer (especially before 65), your risk doubles. The AUA recommends these men start screening at age 40.
- Black men — Prostate cancer incidence is 70% higher in Black men, and mortality is more than double. Earlier and more vigilant screening is warranted, often starting at 40–45.
Who Should Think Twice
Consider Skipping or Delaying
- Men under 40 without risk factors — Prostate cancer is rare before 50. The USPSTF recommends against screening men under 40. False positives cause unnecessary anxiety and invasive follow-up.
- Men over 70 with limited life expectancy — Screening is unlikely to benefit men who won't live long enough for a slow-growing prostate cancer to become symptomatic. The USPSTF recommends against screening men 70+.
- Men who would refuse biopsy or treatment — If you wouldn't follow up on an abnormal result, screening provides anxiety without benefit. Screening only makes sense if you're willing to act on the results.
Alternatives & Complementary Tests
PSA is the first step — not the whole picture. These tools help doctors get a clearer read when PSA results are ambiguous.
Multi-parametric MRI (mpMRI)
Used before biopsy to identify suspicious areas. Can reduce unnecessary biopsies by 27% according to the PRECISION trial.
$500–$1,5004Kscore Test
Blood test measuring four prostate-specific biomarkers. More specific than PSA alone for detecting aggressive cancer.
$300–$500SelectMDx / PHI
Urine and blood biomarker tests that help risk-stratify men with elevated PSA. Helps avoid unnecessary biopsies.
$200–$400Frequently Asked Questions
Final Verdict
PSA testing is a valuable but imperfect tool — and understanding that imperfection is exactly what makes you a smart patient. It's the only widely available, affordable blood test that can flag prostate cancer early enough to cure it. That alone makes it worth discussing with your doctor.
But PSA is not a diagnosis. It's a signal. An elevated number means "investigate further," not "you have cancer." The men who benefit most from PSA testing are those who approach it with clear eyes: they get baseline readings, track changes over time, and work with a doctor who understands that context matters more than any single number.
Our recommendation: If you're 50 or older, or 40+ with risk factors, have the conversation with your doctor. Get a baseline PSA. Know your number. Then decide together how often to monitor. The data supports screening — but only when paired with informed decision-making.
Get Our Screening Checklist